A new dose quantity for evaluation and optimisation of MV photon dose distributions when using advanced algorithms: proof of concept and potential applications

Abstract

Advanced algorithms used in MV photon radiotherapy model radiation transport in any media. They represent a step forward but introduce new uncertainties and questions, including whether to report the doses to water (Dw,m) or medium (Dm,m) voxels, and the impact of fluence changes introduced by surrounding media. These aspects can compromise consistency between both reporting modes and with previous algorithms in which clinical experience is based. This study introduces a new dose quantity, the dose-to-reference-like medium, to overcome the aforementioned shortcomings. It is linked to a reference medium, water in this study (Dw,m*), and defined as the absorbed dose in a voxel of this reference medium surrounded by a reference-like medium with the same radiation transport characteristics as the original one. We propose to derive Dw,m* distributions by post-processing Dw,m or Dm,m applying a correction factor (CF) to each voxel which depends on its composition. We present and justify a simple and straightforward method to obtain CFs that only involves two phantoms with the same density: one with the considered composition and the other with that of the reference medium. A proof of concept was performed in a clinical environment for Acuros XB (AXB) advanced algorithm and 6 MV photon beams. The CFs were derived for the tissues characterised in Acuros. Dw,m* was compared to Dw,m, Dm,m, and Dw,w from AAA analytical algorithm for some virtual and clinical cases. All the previous quantities presented limitations that can be solved by Dw,m*. This new quantity allows the applicability of evaluation parameters, traceability to clinical experience, and isolation of heterogeneity effects to identify optimum plans, offering useful characteristics for plan evaluation and optimisation in clinical practice. Additionally, it also has potential applications in automated treatment planning and multi-centre activities such as clinical trials, audits, benchmarking, and shared models for automation.